Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Lymphatic Research and Biology

Lymphatic Research and BiologyVol. 21, No. 4 AnnouncementFree AccessRosalind Franklin Society Proudly Announces the 2022 Award Recipient for Lymphatic Research and BiologySheila H. RidnerSheila H. RidnerVanderbilt University School of Nursing, Nashville, TN, USASearch for more papers by this authorPublished Online:22 Aug 2023https://doi.org/10.1089/lrb.2023.29148.rfs2022AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail The Rosalind Franklin Society (RFS), in partnership with Mary Ann Liebert, Inc., publishers, enthusiastically congratulate our distinguished recipient of the 2022 annualRFS Award in Sciencefor this journal, which recognizes the outstanding research and published work of women and underrepresented minority scientists, physicians, and engineers.Mary S. Dietrich, Katrina Gaitatzis, Louise Koelmeyer, John Boyages, Vandana G. Abramson, Sarah A. McLaughlin, Nicholas Ngui, Elisabeth Elder, James French, Jeremy Hsu, T. Michael Hughes, Deonni P. Stolldorf, Chirag Shah, and Sheila H. Ridner, “Prospective Surveillance with Compression for Subclinical Lymphedema: Symptoms, Skin, and Quality-of-Life Outcomes,” Lymphatic Research and Biology, http://doi.org/10.1089/lrb.2022.0020.AbstractNewly diagnosed nonmetastatic breast cancer patients underwent a 28-day compression (sleeve and gauntlet) intervention for subclinical breast cancer-related lymphedema (S-BCRL). Physical, emotional, and quality-of-life (QoL) outcomes were examined. Associations of change in extracellular fluid through bioimpedance spectroscopy (BIS) or whole-arm volume change through tape measure with the outcomes were also explored.Improvements with intervention were observed in the proportion of patients reporting symptom scores ≥3 in function (p < 0.01), in biobehavioral (p < 0.05), maximum number of skin conditions, FACT-B, and FACT-B + four. At the study endpoint, compared with those not progressing to chronic breast cancer-related lymphedema, progressing patients had higher overall symptom scores, more skin conditions, and lower total FACT-G and FACT-B scores.BiosketchDr. Ridner is a native of Kentucky. She completed her bachelor's in nursing at the University of Kentucky in 1978. In 1988 she completed her master's in health services administration from the College of St. Francis. In 1999 she resigned her position as a chief executive officer for a mental health hospital to further her graduate education. In 2000 she received a master's in nursing and in 2003 a PhD in nursing science, both from Vanderbilt University. Upon completion of her PhD, she became an inaugural postdoctoral fellow at Vanderbilt University School of Nursing. Dr. Ridner has been on the faculty at Vanderbilt School of Nursing since 2006. She quickly advanced through the tenured academic ranks and was awarded an endowed chair by Vanderbilt University in recognition of research contributions to the university. She has been continually funded for research and is known internationally for her pioneering work in lymphedema. Dr. Ridner currently is the coprimary investigator for a multisite, national study testing a new treatment approach for head and neck cancer patients who develop lymphedema after their cancer treatment. Dr. Ridner is also known for her numerous service activities at local and national levels.FiguresReferencesRelatedDetails Volume 21Issue 4Aug 2023 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:Sheila H. Ridner.Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Lymphatic Research and Biology.Lymphatic Research and Biology.Aug 2023.337-337.http://doi.org/10.1089/lrb.2023.29148.rfs2022Published in Volume: 21 Issue 4: August 22, 2023PDF download